Your Patients Need Acthar Gel — Here's How to Help Them Get It

You've made the clinical decision to prescribe Acthar Gel (repository corticotropin injection). The evidence supports it for your patient's condition, they've failed other therapies, and ACTH therapy is the right next step. Now comes the hard part: actually getting the medication into their hands.

Acthar Gel's specialty pharmacy-only distribution, mandatory prior authorization, and price point of up to $45,600 per vial create a prescribing experience that's dramatically different from most medications. This guide gives your practice concrete steps to improve access and reduce delays for your patients.

Current Availability Landscape

Acthar Gel is not currently listed on the FDA Drug Shortage database, but practical access remains challenging:

• Single manufacturer: Mallinckrodt Pharmaceuticals is the sole producer
• Specialty pharmacy only: Not available at retail pharmacies
• Universal prior authorization: Virtually all payers require PA and step therapy
• High cost: WAC ~$9,061/mL; 5 mL vial ~$45,600
• SelfJect availability: Pre-filled auto-injectors in 40-unit and 80-unit doses for SC administration in adults

For a comprehensive supply and market overview, see our provider briefing on the Acthar Gel shortage.

Why Patients Can't Find Acthar Gel

Understanding the barriers helps your practice address them proactively:

Specialty Pharmacy Bottlenecks

Patients often don't realize Acthar Gel isn't available at their regular pharmacy until they've already tried to fill the prescription. The specialty pharmacy model adds steps: enrollment, insurance verification, clinical review, and scheduled delivery. Each step introduces potential delays.

Prior Authorization Delays

PA timelines range from days to weeks depending on the payer and completeness of initial documentation. Denials require appeals or peer-to-peer reviews, adding more time. For patients in acute flare — MS relapse, nephrotic syndrome exacerbation, lupus flare — these delays can have real clinical consequences.

Cost-Driven Gatekeeping

At $9,061 per mL, payers are aggressive about limiting Acthar Gel approvals. Step therapy requirements, limited authorization durations (often 3-6 months), and re-authorization requirements all serve as cost-control mechanisms that create friction for patients.

Patient Confusion

Many patients don't understand the specialty pharmacy process. They expect to pick up their medication at a pharmacy like any other prescription. Clear communication about what to expect — and proactive support from your practice — makes a significant difference.

What Providers Can Do: 5 Practical Steps

Step 1: Submit Prior Authorization Immediately

Don't wait for the specialty pharmacy to trigger the PA process. Submit prior authorization concurrently with (or even before) sending the prescription. Include comprehensive documentation upfront:

• Confirmed diagnosis with supporting labs/imaging
• Complete treatment history showing failed or inadequate response to corticosteroids and other relevant therapies
• Clinical rationale for Acthar Gel specifically
• Proposed treatment plan with duration and monitoring schedule

Incomplete initial submissions are the single biggest cause of PA delays and denials.

Step 2: Use Medfinder to Identify Pharmacies with Stock

Medfinder for providers lets your staff quickly identify specialty pharmacies that currently have Acthar Gel in stock. This eliminates the guesswork of routing prescriptions to pharmacies that may not have inventory. Bookmark it as a practice resource for all specialty medication prescribing.

Step 3: Enroll Patients in Acthar Patient Support at Prescribing Time

Mallinckrodt's Acthar Patient Support team (1-888-435-2284) provides:

• Insurance benefits investigation
• Prior authorization support
• Specialty pharmacy coordination
• Connection to copay assistance ($0 copay for eligible commercially insured patients, up to $15,000/year)
• Patient assistance program enrollment for uninsured/underinsured patients (at or below 700% FPL)

Enrolling patients at the time of prescribing — rather than after they hit a barrier — proactively prevents many access problems.

Step 4: Prepare for Peer-to-Peer Reviews

PA denials are common with Acthar Gel. When a denial occurs, request a peer-to-peer review promptly. Prepare by having:

• The patient's complete treatment timeline
• Specific documentation of corticosteroid failure (dosing, duration, response metrics)
• Published clinical evidence supporting Acthar Gel for the patient's indication
• Rationale for why alternatives (including Purified Cortrophin Gel) are not appropriate for this specific patient

Step 5: Set Patient Expectations

At the time of prescribing, clearly communicate to patients:

• Acthar Gel is a specialty medication that won't be available at their regular pharmacy
• Insurance authorization is required and may take 1-3 weeks
• The medication will be delivered to their home by a specialty pharmacy
• Financial assistance programs are available and your office will help them enroll
• They should contact your office immediately if they encounter any delays

When to Consider Alternatives

If access barriers are creating clinically unacceptable delays, consider these options while continuing to pursue Acthar Gel authorization:

• Purified Cortrophin Gel: Same ACTH class, ~23% lower cost (~$6,961/mL), approved for most adult indications (not infantile spasms)
• High-dose IV methylprednisolone: For acute flares requiring immediate treatment while waiting for ACTH therapy authorization
• Rituximab: For appropriate autoimmune indications (RA, lupus nephritis) when ACTH therapy is unavailable
• Mycophenolate mofetil: For nephrotic syndrome or lupus nephritis as a maintenance alternative

For detailed clinical comparisons, see our article on alternatives to Acthar Gel.

Workflow Tips for Practice Staff

• Create templates: Develop PA documentation templates for each indication you commonly prescribe Acthar Gel for. Include standard language about step therapy failures and clinical rationale.
• Track authorizations: Maintain a log of pending PAs, denial dates, and appeal deadlines. Missing an appeal window means starting over.
• Build specialty pharmacy relationships: Identify 2-3 specialty pharmacies your practice works with regularly for Acthar Gel. Direct relationships can expedite processing.
• Designate a point person: Having one staff member who owns the specialty medication authorization process improves consistency and reduces dropped balls.
• Bookmark medfinder.com/providers: Use it routinely when routing specialty prescriptions to confirm availability before sending.

Final Thoughts

Getting Acthar Gel to your patients in 2026 requires deliberate practice management alongside clinical expertise. The medication is effective for its approved indications, but the access pathway demands proactive documentation, strategic pharmacy routing, and patient support enrollment from the moment you decide to prescribe.

By integrating these five steps into your prescribing workflow, you can meaningfully reduce delays and help your patients get the treatment they need. For additional resources, visit Medfinder for providers and actharhcp.com.

For patient-facing information you can share, point patients to our guides on finding Acthar Gel in stock and saving money on Acthar Gel.